Introduction: Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction is the standard of care in primary and secondary prevention of cardiovascular disease; nevertheless, a large number of patients treated with statins are unable to reach the recommended LDL-C targets. Therefore, there is need for safe and effective novel therapies for the pharmacological management of hypercholesterolaemia, in addition or as alternative to lipid-lowering therapies (LLT) currently in use. Areas covered: In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent®; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT. The authors review the pharmacological features, clinical efficacy, and safety of alirocumab in lowering LDL-C, and discuss its therapeutic perspectives based on the most recent clinical trials. Expert commentary: Alirocumab causes a marked reduction in LDL-C, presents good safety and tolerability, and represents a promising approach for LDL-C lowering, particularly in patients with intolerance to statin or elevated LDL-C despite maximal statin therapy; nevertheless, further long-term data on safety and efficacy are necessary, such as data on the improvement of cardiovascular outcomes.

Alirocumab for the treatment of hypercholesterolaemia / DELLA PEPA, Giuseppe; Bozzetto, Lutgarda; Annuzzi, Giovanni; Rivellese, ANGELA ALBAROSA. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - 18:(2017), pp. 1-12. [10.1080/17512433.2017.1318063]

Alirocumab for the treatment of hypercholesterolaemia

DELLA PEPA, GIUSEPPE;BOZZETTO, LUTGARDA;ANNUZZI, GIOVANNI;RIVELLESE, ANGELA ALBAROSA
2017

Abstract

Introduction: Prescription of statins for low-density lipoprotein cholesterol (LDL-C) reduction is the standard of care in primary and secondary prevention of cardiovascular disease; nevertheless, a large number of patients treated with statins are unable to reach the recommended LDL-C targets. Therefore, there is need for safe and effective novel therapies for the pharmacological management of hypercholesterolaemia, in addition or as alternative to lipid-lowering therapies (LLT) currently in use. Areas covered: In 2015, the Food and Drug Administration and the European Medicines Agency approved alirocumab (Praluent®; Sanofi), a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9), for the treatment of hypercholesterolaemic patients unable to meet LDL-C targets, as an adjunct to diet in addition/alternative to LLT. The authors review the pharmacological features, clinical efficacy, and safety of alirocumab in lowering LDL-C, and discuss its therapeutic perspectives based on the most recent clinical trials. Expert commentary: Alirocumab causes a marked reduction in LDL-C, presents good safety and tolerability, and represents a promising approach for LDL-C lowering, particularly in patients with intolerance to statin or elevated LDL-C despite maximal statin therapy; nevertheless, further long-term data on safety and efficacy are necessary, such as data on the improvement of cardiovascular outcomes.
2017
Alirocumab for the treatment of hypercholesterolaemia / DELLA PEPA, Giuseppe; Bozzetto, Lutgarda; Annuzzi, Giovanni; Rivellese, ANGELA ALBAROSA. - In: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. - ISSN 1751-2433. - 18:(2017), pp. 1-12. [10.1080/17512433.2017.1318063]
File in questo prodotto:
File Dimensione Formato  
Alirocumab for the treatment of hypercholesterolaemia.pdf

accesso aperto

Licenza: Accesso privato/ristretto
Dimensione 833.55 kB
Formato Adobe PDF
833.55 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/672378
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 6
social impact